NextCure, Inc. Common Stock
$6.12
Market Cap
$28.01M
Shares Outstanding
4.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 9, 2019
Round Lot
100
Locale
US
Day Open
$5.87
Day High
$6.27
Day Low
$5.67
Volume
103.9K
VWAP
$6.02
Prev Close
$5.67
Transactions
--
Acc. Volume
--
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
NextCure, Inc. Common Stock (NXTC) closed the 2026-09-18 session at $6.12, up 7.94% versus the previous close (+0.45). The stock opened at $5.87 and traded between $5.67 and $6.27 during that session. Session trading volume was 104K shares. The volume-weighted average price (VWAP) is $6.02.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
NextCure, Inc. Common Stock has a market capitalization of $28.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. NXTC is listed on the XNAS exchange. The company employs approximately 40 people. NextCure, Inc. Common Stock is headquartered in BELTSVILLE, MD. The recorded listing date is 2019-05-09.
On this page you can find market NXTC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.